JP2023119042A5 - - Google Patents

Download PDF

Info

Publication number
JP2023119042A5
JP2023119042A5 JP2023113057A JP2023113057A JP2023119042A5 JP 2023119042 A5 JP2023119042 A5 JP 2023119042A5 JP 2023113057 A JP2023113057 A JP 2023113057A JP 2023113057 A JP2023113057 A JP 2023113057A JP 2023119042 A5 JP2023119042 A5 JP 2023119042A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
alkyl
compound
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023113057A
Other languages
English (en)
Japanese (ja)
Other versions
JP7689160B2 (ja
JP2023119042A (ja
Filing date
Publication date
Priority claimed from JP2020534302A external-priority patent/JP2021506904A/ja
Application filed filed Critical
Publication of JP2023119042A publication Critical patent/JP2023119042A/ja
Priority to JP2025034943A priority Critical patent/JP2025078783A/ja
Publication of JP2023119042A5 publication Critical patent/JP2023119042A5/ja
Application granted granted Critical
Publication of JP7689160B2 publication Critical patent/JP7689160B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023113057A 2017-12-22 2023-07-10 Cns障害の処置のための組成物および方法 Active JP7689160B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025034943A JP2025078783A (ja) 2017-12-22 2025-03-05 Cns障害の処置のための組成物および方法

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US201762610067P 2017-12-22 2017-12-22
US62/610,067 2017-12-22
US201762612070P 2017-12-29 2017-12-29
US201762611977P 2017-12-29 2017-12-29
US201762612067P 2017-12-29 2017-12-29
US201762612164P 2017-12-29 2017-12-29
US62/612,164 2017-12-29
US62/611,977 2017-12-29
US62/612,067 2017-12-29
US62/612,070 2017-12-29
US201862765164P 2018-08-17 2018-08-17
US62/765,164 2018-08-17
US201862728499P 2018-09-07 2018-09-07
US62/728,499 2018-09-07
US201862737559P 2018-09-27 2018-09-27
US62/737,559 2018-09-27
US201862754977P 2018-11-02 2018-11-02
US62/754,977 2018-11-02
JP2020534302A JP2021506904A (ja) 2017-12-22 2018-12-21 Cns障害の処置のための組成物および方法
PCT/US2018/067306 WO2019126761A1 (en) 2017-12-22 2018-12-21 Compositions and methods for treating cns disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020534302A Division JP2021506904A (ja) 2017-12-22 2018-12-21 Cns障害の処置のための組成物および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025034943A Division JP2025078783A (ja) 2017-12-22 2025-03-05 Cns障害の処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2023119042A JP2023119042A (ja) 2023-08-25
JP2023119042A5 true JP2023119042A5 (https=) 2025-03-14
JP7689160B2 JP7689160B2 (ja) 2025-06-05

Family

ID=65234664

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020534302A Withdrawn JP2021506904A (ja) 2017-12-22 2018-12-21 Cns障害の処置のための組成物および方法
JP2023113057A Active JP7689160B2 (ja) 2017-12-22 2023-07-10 Cns障害の処置のための組成物および方法
JP2025034943A Pending JP2025078783A (ja) 2017-12-22 2025-03-05 Cns障害の処置のための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020534302A Withdrawn JP2021506904A (ja) 2017-12-22 2018-12-21 Cns障害の処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025034943A Pending JP2025078783A (ja) 2017-12-22 2025-03-05 Cns障害の処置のための組成物および方法

Country Status (14)

Country Link
US (2) US20220315621A1 (https=)
EP (1) EP3728285B1 (https=)
JP (3) JP2021506904A (https=)
KR (1) KR20200104349A (https=)
CN (3) CN111741965B (https=)
AR (1) AR114044A1 (https=)
AU (2) AU2018392093B2 (https=)
BR (1) BR112020012761A2 (https=)
CA (1) CA3086189A1 (https=)
IL (2) IL275506A (https=)
MA (1) MA51316A (https=)
MX (3) MX2020006608A (https=)
TW (1) TWI907333B (https=)
WO (1) WO2019126761A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201606063RA (en) 2012-01-23 2016-09-29 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CN111741965B (zh) 2017-12-22 2024-06-25 萨奇治疗股份有限公司 治疗中枢神经系统疾病的组合物和方法
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
EP3750909B1 (en) * 2018-02-11 2025-03-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Steroid derivative regulators, method for preparing the same, and uses thereof
CN113166193B (zh) 2018-10-12 2025-08-19 萨奇治疗股份有限公司 用于治疗cns病症的在位置10处被环状基团取代的神经活性类固醇
IL283629B2 (en) 2018-12-05 2026-03-01 Sage Therapeutics Inc Neuroactive steroids and methods of using them
CN116589521B (zh) * 2019-01-08 2025-07-11 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
AU2020304673A1 (en) * 2019-06-27 2022-01-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US20230257415A1 (en) 2019-06-27 2023-08-17 Sage Therapeutics, Inc. Compounds for treating cns disorders
JP7787635B2 (ja) * 2019-06-27 2025-12-17 セージ セラピューティクス, エルエルシー Cns障害を治療するための組成物及び方法
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2022246634A1 (en) * 2021-05-25 2022-12-01 Zhejiang Jiachi Development Pharmaceuticals Ltd. Compositions for treating insomnia and uses thereof
EP4725951A1 (en) * 2023-07-14 2026-04-15 Chengdu Kanghong Pharmaceutical Co., Ltd. Crystal form of steroid compound and use thereof
CN119529013B (zh) * 2024-11-25 2025-11-07 湖南新合新生物医药有限公司 一种祖拉诺龙中间体的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1380246A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
DE2445161A1 (de) * 1974-09-19 1976-04-01 Schering Ag D-homo-20-ketopregnane ii
ES432106A1 (es) * 1973-11-30 1976-11-01 Schering Ag Procedimiento para la preparacion de d-homo-20-cetopregna- nos.
IL48628A0 (en) * 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) * 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) * 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US5028631A (en) 1987-11-25 1991-07-02 Schwartz Arthur G Homoandrostan-17-one and homoandrosten-17-ones
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
DE19581854T1 (de) 1994-12-03 1997-12-04 Dong Kook Pharmaceutical Co Asiatsäure-Derivate, Verfahren zu ihrer Herstellung und sie enthaltendes dermatologisches Agens
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
AU2001294959A1 (en) 2000-09-29 2002-04-08 Robert M. Carlson Triterpenes having antibacterial activity
JP6470258B2 (ja) * 2013-04-17 2019-02-13 セージ セラピューティクス, インコーポレイテッド 19−ノルc3,3−ジ置換c21−n−ピラゾリルステロイドおよびその使用方法
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
CN111741965B (zh) 2017-12-22 2024-06-25 萨奇治疗股份有限公司 治疗中枢神经系统疾病的组合物和方法
CN116589521B (zh) 2019-01-08 2025-07-11 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
AU2020304673A1 (en) 2019-06-27 2022-01-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders

Similar Documents

Publication Publication Date Title
JP2023119042A5 (https=)
JP6933770B2 (ja) Hivカプシド阻害剤のコリン塩形態
ES2660831T3 (es) Derivados de imidazol condensados útiles como inhibidores de IDO
JP2018505898A5 (https=)
WO2019023145A1 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY
JP2017531020A5 (https=)
CA2972014A1 (en) Fused pyrimidine compounds for the treatment of hiv
AU2010308306A1 (en) Combination cancer therapy with HSP90 inhibitory compounds
JP2012505836A5 (https=)
JP2019500387A5 (https=)
JP2014524472A5 (https=)
RU2008152763A (ru) Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии
KR20160085917A (ko) 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
JPWO2020118060A5 (https=)
RU2010154173A (ru) Режим введения нитрокатехолов
JP2019515909A (ja) 慢性リンパ性白血病の治療を目的とするhdac阻害剤単独またはbtk阻害剤との配合物
CA2415577A1 (en) Use of cox-2 inhibitors for preventing immunodeficiency
JP2005515976A5 (https=)
JP2020500868A5 (https=)
JPWO2020132504A5 (https=)
RU2016133336A (ru) Новые производные CYP-эйкозаноидов
JPWO2021262836A5 (https=)
JPWO2020077255A5 (https=)
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
JP5344923B2 (ja) 増殖性疾患の治療のためのチアゾール